Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...335336337338339340341342343344345...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. (Pubmed Central) -  Apr 15, 2022   
    Cortisol excess was defined by clinical assessment and the 1-mg overnight dexamethasone-suppression test (serum cortisol: 138 nmol/L and absence of typical clinical Cushing syndrome [CS] features, definitive MACS [MACS-2])...A cardiometabolic risk condition, MACS predominantly affects women and warrants regular assessment for hypertension and type 2 diabetes. Diabetes UK, the European Commission, U.K. Medical Research Council, the U.K. Academy of Medical Sciences, the Wellcome Trust, the U.K. National Institute for Health Research, the U.S. National Institutes of Health, the Claire Khan Trust Fund at University Hospitals Birmingham Charities, and the Mayo Clinic Foundation for Medical Education and Research.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Review, Journal:  Safety profile of COVID-19 drugs in a real clinical setting. (Pubmed Central) -  Apr 15, 2022   
    In contrast, ample well-conducted studies have approved the use of remdesivir, tocilizumab, and dexamethasone under certain conditions in COVID-19 patients. Consequently, it is significant to establish a strong surveillance system in order to monitor the proper safety and toxicity profile of the potential anti-COVID-19 drugs with good clinical outcomes.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, IO biomarker:  Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells. (Pubmed Central) -  Apr 15, 2022   
    However, LINC00461 knockdown enhanced the inhibitory effects on cell proliferation and the induction of cell apoptosis induced by dexamethasone. In summary, MSCs inhibited the effects of dexamethasone on multiple myeloma and its regulatory effects were associated with LINC00461.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Naringenin Improves Ovalbumin-Induced Allergic Asthma in Rats through Antioxidant and Anti-Inflammatory Effects. (Pubmed Central) -  Apr 15, 2022   
    Then, on days 21, 22, and 23, they were sensitized with the inhalation of ovalbumin), AS treated with dexamethasone (AS, 1 mg/kg/day, orally) [AS + D1], AS treated with naringenin (20 mg/kg/day, orally) [AS + N20], and AS treated with naringenin (40 mg/kg/day, orally) [AS + N40]...Histopathological analysis data also confirm the results. Naringenin improves the symptoms of allergic asthma through antioxidant and anti-inflammatory effects.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Trial completion date, Trial primary completion date:  Ixazomib + Pomalidomide + Dexamethasone In MM (clinicaltrials.gov) -  Apr 15, 2022   
    P1/2,  N=61, Recruiting, 
    Naringenin improves the symptoms of allergic asthma through antioxidant and anti-inflammatory effects. Trial completion date: Mar 2022 --> Mar 2024 | Trial primary completion date: Mar 2022 --> Mar 2024
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Clinical, Journal:  Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. (Pubmed Central) -  Apr 14, 2022   
    Despite having a more severe disease profile, patients with PM/DM submitted to pulse IVMP or pulse IVMP + IVIG during the first year of diagnosis had a higher HR for complete clinical response, whereas the combination of pulse IVMP + IVIG had an association with CS discontinuation. Prospective long-term studies are warranted to confirm these benefits of early pulse IVMP and IVIG on patients with PM/DM.
  • ||||||||||  Tarpeyo (budesonide) / Calliditas, Stada
    Journal:  First Drug to Reduce Proteinuria in Berger's Disease. (Pubmed Central) -  Apr 14, 2022   
    Budesonide (Tarpeyo) has received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy, also known as Berger's disease.Nurses should assess if any coprescribed drugs could induce a drug-drug interaction via the cytochrome P-450 isoenzyme system. Because budesonide causes immunosuppression, patients are at high risk for developing infections and should be told to avoid anyone who is known to have an infection.
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
    Journal:  Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere® (Pubmed Central) -  Apr 14, 2022   
    As compared to glycopyrronium/formoterol combination, Trixeo Aerosphere® reduces exacerbation rate, improved quality of life and most importantly reduces mortality with a benefit increasing with blood eosinophil count. Trixeo Aerosphere® 320/18/9.6 is delivered twice daily 2 inhalations and is indicated in moderate to severe COPD insufficiently controlled by LABA/LAMA (long-acting ?2-adrenergic receptor agonist/ long-acting ?2-muscarinic receptor agonist) or ICS/LABA (inhaled corticosteroid/long-acting ?2-adrenergic receptor agonist).
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial completion date, Combination therapy:  Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) -  Apr 14, 2022   
    P1/2,  N=68, Active, not recruiting, 
    Trixeo Aerosphere® 320/18/9.6 is delivered twice daily 2 inhalations and is indicated in moderate to severe COPD insufficiently controlled by LABA/LAMA (long-acting ?2-adrenergic receptor agonist/ long-acting ?2-muscarinic receptor agonist) or ICS/LABA (inhaled corticosteroid/long-acting ?2-adrenergic receptor agonist). Trial completion date: Feb 2022 --> Feb 2023
  • ||||||||||  Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex
    Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis (Dock 1) -  Apr 14, 2022 - Abstract #ECFS2022ECFS_596;    
    He was established on Kaftrio® and had normal lung function (FEV1 >100%)...He was commenced on intravenous tobramycin, ceftazidime and dexamethasone.Over the next 24 hours, his work of breathing increased and he developed acute confusion despite successful management of his hypoxia with non-invasive ventilation...His antibiotic regimen was changed to meropenem and co-trimoxazole... To our knowledge, this is the first reported case of necrotising pneumonia (NP) associated with COVID-19 in an individual with CF and the first associated with Nocardia infection. We hope by reporting this case it will highlight the continued risks of COVID-19 infection relevant to individuals with CF of any age.
  • ||||||||||  bortezomib / Generic mfg., pomalidomide / Generic mfg.
    Trial completion date, Trial primary completion date:  First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD (clinicaltrials.gov) -  Apr 14, 2022   
    P1,  N=36, Active, not recruiting, 
    We hope by reporting this case it will highlight the continued risks of COVID-19 infection relevant to individuals with CF of any age. Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
  • ||||||||||  prednisone delayed-release tablet / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  GWIIRT: Gulf War Illness Inflammation Reduction Trial (clinicaltrials.gov) -  Apr 14, 2022   
    P2,  N=83, Completed, 
    Dexamethasone may alleviate the reduction in E-cadherin and p120 protein expression caused by inflammatory mediators. Recruiting --> Completed | Phase classification: P3 --> P2 | Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Jan 2020 --> Dec 2021
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Enrollment open:  Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (clinicaltrials.gov) -  Apr 13, 2022   
    P3,  N=150, Recruiting, 
    Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Not yet recruiting --> Recruiting
  • ||||||||||  triamcinolone acetonide / Generic mfg., amikacin sulfate / Generic mfg.
    Clinical, Journal:  Comparison of equine synovial sepsis rate following intrasynovial injection in ambulatory versus hospital settings. (Pubmed Central) -  Apr 13, 2022   
    The frequency of synovial sepsis in this population of horses was not higher when injections were performed in the field or without concurrent antibiotic administration. These data may help to inform practitioners and clients regarding the relative potential risk of complications following intrasynovial medication in different environmental settings.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Purification of chitosanases produced by Bacillus toyonensis CCT 7899 and functional oligosaccharides production. (Pubmed Central) -  Apr 13, 2022   
    The treatment with COS promoted a decrease of paw edema at all evaluated times and the AUC0-4h, proving that COS produced showed activity in acute inflammation like commercial anti-inflammatory Dexamethasone (corticosteroid). Therefore, the strategy used to purification was successfully applied and it was possible to generate bioactive oligosaccharides with potential pharmacological use.